Provectus Pharmaceuticals Inc. Begins Phase 2 Clinical Trial for Psoriasis

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has obtained approval to begin Phase 2 clinical testing of PH-10, the company’s topical drug for dermatology, for the treatment of psoriasis. The study is designed to evaluate efficacy of PH-10 in a total of twenty-five subjects with moderate to severe forms of the disease.

Back to news